HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Cornelius M. Dyke Nicholas G. Smedira Harry L. McCarthy, II Ronald Kirshner Bruce D. Spiess Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dyke, C. M. Articles by Spiess, B. D. Search for Related Content PubMed PubMed Citation Articles by Dyke, C. M. Articles by Spiess, B. D. Related Collections Electrophysiology - arrhythmias Related Articles

J Thorac Cardiovasc Surg 2006;131:533-539
© 2006 The American Association for Thoracic Surgery

Surgery for Acquired Cardiovascular Disease

A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study

Gaston Memorial Hospital, Gastonia, NC

Received for publication June 17, 2005; revisions received October 6, 2005; accepted for publication October 20, 2005.

^_* Address for reprints: Cornelius M. Dyke, MD, Carolina Cardiovascular and Thoracic Surgery Associates, Gaston Memorial Hospital, 2555 Court Drive, Suite 200, Gastonia, NC, 28056 (Email: dykec{at}gmh.org).

OBJECTIVES: Unfractionated heparin and its antidote, protamine sulfate, allow for rapid and reversible anticoagulation during cardiac surgery with cardiopulmonary bypass, yet limitations exist, including a variable dose-response, dependence on a cofactor for anticoagulant effect, and antigenic potential. This trial was performed to evaluate the safety and efficacy of bivalirudin as an alternative to heparin with protamine reversal in on-pump cardiac surgery.

METHODS: We conducted a randomized, open-label, multicenter trial comparing heparin with protamine reversal to bivalirudin in patients undergoing cardiac surgery with cardiopulmonary bypass. The primary objective was to demonstrate comparable rates of in-hospital procedural success defined as freedom from death, Q-wave myocardial infarction, stroke, or repeat revascularization. Twenty-one institutions enrolled 101 patients randomized to bivalirudin and 49 patients to heparin treatment.

RESULTS: The primary end point of procedural success was not significantly different between the bivalirudin arm and the heparin/protamine arms at 7 days, 30 days, or 12 weeks' follow-up. Adequate anticoagulation was achieved in all patients. Secondary end points including mortality, 24-hour blood loss, overall incidence of transfusions, and duration of surgery were similar between the two arms.

CONCLUSIONS: Bivalirudin is a safe and effective anticoagulant for patients undergoing a wide range of cardiac surgical procedures with cardiopulmonary bypass. Procedural success rates with bivalirudin were similar to rates in patients receiving heparin anticoagulation, with no difference in mortality. Avoidance of blood stasis and attention to the intraoperative medical management of patients is critical for successful use of bivalirudin during cardiopulmonary bypass.

Related Articles

Anticoagulation for cardiopulmonary bypass: Is a replacement for heparin on the horizon?

Theodore E. Warkentin
J. Thorac. Cardiovasc. Surg. 2006 131: 515-516. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				Q. A Czosnowski, S. W Finks, and K. C Rogers Bivalirudin for Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiovascular Surgery Ann. Pharmacother., September 1, 2008; 42(9): 1304 - 1309. [Abstract] [Full Text] [PDF]

				T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]

				I. Apostolidou, M. F. Sweeney, E. Missov, L. D. Joyce, R. John, and R. C. Prielipp Acute Left Atrial Thrombus After Recombinant Factor VIIa Administration During Left Ventricular Assist Device Implantation in a Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., February 1, 2008; 106(2): 404 - 408. [Abstract] [Full Text] [PDF]

				A. F. Merry Focus on Thrombin: Alternative Anticoagulants Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 256 - 260. [Abstract] [PDF]

				C. M. Dyke, G. Aldea, A. Koster, N. Smedira, E. Avery, S. Aronson, B. D. Spiess, and A. M. Lincoff Off-Pump Coronary Artery Bypass With Bivalirudin for Patients With Heparin-Induced Thrombocytopenia or Antiplatelet Factor Four/Heparin Antibodies Ann. Thorac. Surg., September 1, 2007; 84(3): 836 - 839. [Abstract] [Full Text] [PDF]

				J. H. Levy, K. A. Tanaka, and M. J. Hursting Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Anesth. Analg., September 1, 2007; 105(3): 570 - 582. [Abstract] [Full Text] [PDF]

				A. Koster, Y. Weng, W. Bottcher, T. Gromann, H. Kuppe, and R. Hetzer Successful Use of Bivalirudin as Anticoagulant for ECMO in a Patient With Acute HIT Ann. Thorac. Surg., May 1, 2007; 83(5): 1865 - 1867. [Abstract] [Full Text] [PDF]

				A. Koster, C. M. Dyke, G. Aldea, N. G. Smedira, H. L. McCarthy II, S. Aronson, R. Hetzer, E. Avery, B. Spiess, and A. M. Lincoff Bivalirudin During Cardiopulmonary Bypass in Patients With Previous or Acute Heparin-Induced Thrombocytopenia and Heparin Antibodies: Results of the CHOOSE-ON Trial Ann. Thorac. Surg., February 1, 2007; 83(2): 572 - 577. [Abstract] [Full Text] [PDF]

				F. Pappalardo, A. Franco, G. Crescenzi G, A. Poli, A. Zangrillo, and A. Koster Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy Perfusion, January 1, 2007; 22(1): 67 - 69. [Abstract] [PDF]

				L. H. Edmunds Jr and R. W. Colman Thrombin During Cardiopulmonary Bypass Ann. Thorac. Surg., December 1, 2006; 82(6): 2315 - 2322. [Abstract] [Full Text] [PDF]

				Anticoagulation for cardiopulmonary bypass: is a replacement for heparin on the horizon? J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 515 - 516.